Payment overview · 2025
General Payments
$454.80
24 reported records · 15 companies
Healthcare provider profile · identity verified
Patrick J. Edwards, MD
Allopathic & Osteopathic Physicians|Family Medicine · NEWTON, IA · NPI 1740214873
Verified facts
What the public records show
CMS Open Payments records show Patrick J. Edwards, MD received $454.80 in general payments during 2025 across 24 reported records.
PFIZER INC. accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $77.93 | 17.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $77.41 | 17.0% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $47.64 | 10.5% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $31.40 | 6.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.41 | 5.6% | 2 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $24.16 | 5.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $22.78 | 5.0% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.75 | 5.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $21.98 | 4.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.65 | 4.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $19.22 | 4.2% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $16.01 | 3.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.89 | 3.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.59 | 3.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $14.98 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $454.80 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $71.10 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $44.85 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $33.08 | 2 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $31.40 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $28.18 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $25.41 | 2 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $24.16 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $22.78 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.75 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $19.22 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 164 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
164 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 478 | 112 |
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 113 |
| Lisinopril | Lisinopril | 407 | 107 |
| Omeprazole | Omeprazole | 365 | 105 |
| Levothyroxine Sodium | Levothyroxine Sodium | 359 | 93 |
| Furosemide | Furosemide | 311 | 72 |
| Potassium Chloride | Potassium Chloride | 302 | 71 |
| Sertraline Hcl | Sertraline Hcl | 245 | 44 |
| Simvastatin | Simvastatin | 243 | 72 |
| Metoprolol Succinate | Metoprolol Succinate | 234 | 55 |
| Losartan Potassium | Losartan Potassium | 214 | 68 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 38 |
| Gabapentin | Gabapentin | 201 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 200 | 43 |
| Metformin Hcl | Metformin Hcl | 180 | 57 |
| Tramadol Hcl | Tramadol Hcl | 171 | 41 |
| Eliquis | Apixaban | 164 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 147 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 146 | 43 |
| Trazodone Hcl | Trazodone Hcl | 126 | 25 |
| Carvedilol | Carvedilol | 124 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 124 | 33 |
| Quetiapine Fumarate | Quetiapine Fumarate | 123 | 27 |
| Lorazepam | Lorazepam | 120 | 27 |
| Donepezil Hcl | Donepezil Hcl | 115 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 100 | 14 |
| Memantine Hcl | Memantine Hcl | 91 | 12 |
| Xarelto | Rivaroxaban | 88 | 11 |
| Alprazolam | Alprazolam | 85 | 16 |
| Benazepril Hcl | Benazepril Hcl | 84 | 24 |
| Famotidine | Famotidine | 82 | 19 |
| Allopurinol | Allopurinol | 80 | 19 |
| Warfarin Sodium | Warfarin Sodium | 77 | 21 |
| Cephalexin | Cephalexin | 74 | 44 |
| Pregabalin | Pregabalin | 69 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 67 | 11 |
| Meloxicam | Meloxicam | 66 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 65 | 17 |
| Jardiance | Empagliflozin | 59 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | suppressed |
| Fentanyl | Fentanyl | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 56 | 12 |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Prednisone | Prednisone | 53 | 24 |
| Celecoxib | Celecoxib | 52 | 13 |
| Myrbetriq | Mirabegron | 51 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | suppressed |
| Levetiracetam | Levetiracetam | 49 | suppressed |
| Spironolactone | Spironolactone | 49 | 15 |
| Clonidine Hcl | Clonidine Hcl | 48 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 47 | 12 |
| Ozempic | Semaglutide | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 44 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 40 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 17 |
| Glipizide | Glipizide | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 12 |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | 12 |
| Risperidone | Risperidone | 37 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Carbamazepine | Carbamazepine | 30 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 30 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Amoxicillin | Amoxicillin | 29 | 12 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 28 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | suppressed |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Humulin R | Insulin Regular, Human | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Diazepam | Diazepam | 17 | suppressed |
| Lorazepam Intensol | Lorazepam | 17 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Verapamil Sr | Verapamil Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $454.80 · 24 records | PFIZER INC. | ABRYSVO, BEYFORTUS, CAPLYTA, COMIRNATY, ELIQUIS, FARXIGA, FLUZONE HIGH-DOSE, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, Heplisav-B, JARDIANCE, MENQUADFI, MOUNJARO, Ozempic, PREVNAR 20, Rybelsus, SPRINT PNS System, UBRELVY, VOQUEZNA, VYNDAMAX, Veozah, ZEPBOUND, ZURZUVAE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error